MOTS-c vs Survodutide
Both MOTS-c and Survodutide are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Survodutide
Evidence ASurvodutide (BI 456906)
A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
View full Survodutide profile →Side-by-Side
| Attribute | MOTS-c | Survodutide |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — research peptide; multiple early-phase clinical trials | Not FDA-approved — Phase 3 trials for obesity and MASH |
| Typical Dose | 5–10 mg, 2–3 times weekly (subcutaneous) | Trial range: 0.6–6 mg weekly (subcutaneous) |
| Clinics Indexed | 22 | 6 |
| Categories | metabolic, longevity | weight-loss, metabolic |
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Key reported benefits — Survodutide
- ✓Weight loss
- ✓MASH resolution
- ✓Glucose control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.